$CLNE

Clean Energy Fuels (CLNE) Q2 2026 Earnings Call Transcript

Clean Energy Fuels (CLNE) reported Q2 2026 revenue of $106.4 million and a GAAP net loss of $14.9 million, with adjusted EBITDA of $16.0 million. Fuel volume rose to 81.8 million gallons, including 63.2 million gallons of RNG. Full-year 2026 adjusted EBITDA guidance is $70 million to $75 million. Cash was $138 million. Management cited regulatory timing risks around Section 45Z.

Original reporting
Published Aug 14, 2026, 12:15 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 14, 2026, 12:32 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Clean Energy Fuels (CLNE) Q2 2026 Earnings Call Transcript — source image
Decision brief

The 30-second read

$CLNENeutralMed
01

Why it matters

Traders can update expectations for 2026 profitability based on the maintained adjusted EBITDA range, the GAAP net loss range, and the company’s stated sensitivity to Section 45Z rule finalization timing.

02

Market read

The newest actionable items are the Q2 datapoints and the maintained 2026 guidance ranges, plus management’s stated regulatory timing risk for Section 45Z.

03

What to watch

Hydrogen contract value ($27M) and upstream ramp-ups are positives, but the call also notes slower adoption of new natural gas engines due to uncertainty around 2027 EPA standards, which could cap volume conversion.

Relevance 8/10Novelty 7/10Timing: post-Q2 earnings call, guidance and regulatory timing assumptions for 2026

Background

The article is a transcript of Clean Energy Fuels’ Q2 2026 earnings call, covering results, segment volumes, and full-year guidance assumptions tied to federal clean-fuel credit rules.

Company-level read

Ticker impact

$CLNENeutralMedium confidence
Context

Clean Energy Fuels reported Q2 2026 revenue of $106.4M, a $14.9M GAAP net loss, and maintained 2026 adjusted EBITDA guidance of $70M to $75M.

Expected impact

Moderate volatility risk around 2026 guidance credibility, especially if Section 45Z timing or EPA standards clarity disappoints.

Evidence & confidence

The call provides multiple fresh datapoints (Q2 results, full-year GAAP loss range, adjusted EBITDA range, and explicit risk linkage to Section 45Z rule timing) that can drive repricing, but it is still a transcript-style earnings disclosure rather than a surprise policy decision.

Market effects

Reinforces that RNG and clean-fuel station buildout economics remain sensitive to federal credit rule timing (Section 45Z) and EPA standards clarity.

Highlights Western Canada station completion and Canada diesel tax dynamics supporting CNG/RNG competitiveness for high-mileage fleets.

Limited direct global linkage, but hydrogen infrastructure contracting signals continued investment in low-emission transport fuels.

Counterpoint

Despite maintained guidance, the explicit risk that delayed Section 45Z rules could push adjusted EBITDA below $70M suggests the market may be underpricing regulatory timing risk.

Key entities

  • Clean Energy Fuels

    Reported Q2 2026 results and maintained 2026 guidance, with explicit downside risk tied to potential delay or reduced benefit of Section 45Z clean fuel production credit rules.

  • Orange County Transportation Authority

    Awarded a hydrogen design and construction contract valued at $27M, described as the company’s largest hydrogen project to date.

  • Federal Transit Administration

    Announced it will prioritize low-emission solutions like CNG over zero-emission buses for funding, per management commentary.

Related articles

$CLNEMed

Why Clean Energy Fuels Stock Is Soaring Today

Clean Energy Fuels (NASDAQ: CLNE) reported Q2 2026 revenue of $106.4 million, above analysts’ $104.7 million estimate, and adjusted EPS of -$0.01 matching expectations. Management projected 2026 upstream renewable natural gas adjusted EBITDA of $3.0 million to $5.1 million versus -$12 million in 2025. Shares were up 6.8% at 2:59 p.m. ET.

$CLNEMed

Why Clean Energy Fuels Stock Is Soaring Today

Clean Energy Fuels (CLNE) shares rose about 6.8% in afternoon trading after the company reported Q2 2026 revenue of $106.4 million, above analysts’ $104.7 million estimate, and adjusted EPS of -$0.01. Management projected 2026 upstream renewable natural gas adjusted EBITDA of $3 million to $5.1 million versus -$12 million in 2025.

$CLNEMed

Clean Energy Fuels Corp. (CLNE): Results of Operations and Financial Condition

Clean Energy Fuels Corp. (CLNE) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 clne-20260806xex99d1.htm EX-99.1 Exhibit 99.1 ​ Clean Energy Reports Revenue of $ 106.4 Million and 63.2 Million RNG Gallons Sold for the Second Quarter of 2026. NEWPORT BEACH, Calif. — (BUSINESS WIRE) — August 6, 2026 — Clean Energy Fuels Corp. (NASDAQ: CLNE) (“Clean E

$CLNEMedAI 8/10

Clean Energy Fuels Corp. Awarded $27.5M Contract

Clean Energy Fuels Corp. (Nasdaq: CLNE) said it was awarded a $27.5 million contract by Orange County Transportation Authority to design and build a private hydrogen fueling station at OCTA’s Garden Grove bus base. Completion is expected in 2028. The company’s shares rose about 1% after hours to $1.88.

$METAMedAI 8/10

Clean Max Hits 52-week High as Meta’s 900 MW Green Energy Bet Ignites Investor Optimism

Clean Max Enviro Energy Solutions hit a 52-week/all-time high of ₹1,421.20 (52-week low ₹727.10) after expanding its partnership with Meta Platforms for 900+ MW of renewable capacity in India. The agreement covers 837 MW of new solar and wind projects in Rajasthan and Karnataka, with Meta buying 100% of environmental attributes. Clean Max’s contracted portfolio is ~5.7 GW, and shares rose 17.9% WoW.

$HCMMedAI 8/10

Why is HUTCHMED stock surging today?

HUTCHMED shares rose nearly 5% to HK$20.14 after the company reported positive topline results from its SAFFRON Phase III trial. The study of savolitinib (Orpathys) plus osimertinib (Tagrisso) in EGFR-mutant NSCLC met co-primary endpoints, improving progression-free and overall survival in patients with high MET overexpression or amplification after osimertinib progression. The move followed recent analyst target cuts.